Given the potential advantages of targeting multiple subsites within cholinesterases, we developed a novel series of coumarin–triazole–isatin hybrids, aiming to enhance both cholinesterase inhibition and modulate amyloid aggregation in AD. The gene discussed is BCHE; the disease is Alzheimer disease.